Amir Goldkorn
Contact
American Federation for Medical Research: Outstanding Investigator Award, 2015
Western Society of Clinical Investigation: Elected Member, 2014
American Society of Clinical Oncology: Merit Award, 2012
Stop Cancer Foundation: Research Career Development Award, 2007-2010
American Society of Clinical Oncology: Young Investigator Award, 2006-2007
UCLA School of Medicine: Letters of Distinction, 1996-1997
Harvard University: Harvard College Scholarship, 1990-1994
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer Curr Oncol Rep. 2022 Oct; 24(10):1287-1298. . View in PubMed
FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer Cancers (Basel). 2022 Mar 28; 14(7). . View in PubMed
Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis Int J Mol Sci. 2022 Feb 25; 23(5). . View in PubMed
Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time Sci Rep. 2022 04 01; 12(1):5518. . View in PubMed
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) J Clin Oncol. 2022 10 01; 40(28):3301-3309. . View in PubMed
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) Clin Cancer Res. 2021 05 01; 27(9):2435-2441. . View in PubMed
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) Clin Cancer Res. 2021 04 01; 27(7):1967-1973. . View in PubMed
Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype Int J Cancer. 2020 06 01; 146(11):3065-3076. . View in PubMed
Cancer transcriptomic profiling from rapidly enriched circulating tumor cells Int J Cancer. 2020 05 15; 146(10):2845-2854. . View in PubMed
Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed
Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research Urol Oncol. 2019 05; 37(5):313-317. . View in PubMed
Current status of liquid biopsies for the detection and management of prostate cancer Cancer Manag Res. 2019; 11:5271-5291. . View in PubMed
Multiparametric liquid biopsy analysis in metastatic prostate cancer JCI Insight. 2019 03 07; 4(5). . View in PubMed
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. . View in PubMed
Development and Application of Liquid Biopsies in Metastatic Prostate Cancer Curr Oncol Rep. 2018 03 23; 20(4):35. . View in PubMed
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 Cancer Treat Res Commun. 2018; 16:18-23. . View in PubMed
Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond Cancer Treat Res. 2018; 175:87-104. . View in PubMed
The evolution of chemotherapy for the treatment of prostate cancer Ann Oncol. 2017 Nov 01; 28(11):2658-2669. . View in PubMed
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421 Clin Genitourin Cancer. 2017 12; 15(6):635-641. . View in PubMed
Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine Front Oncol. 2017; 7:6. . View in PubMed
Telomere and Telomerase Therapeutics in Cancer Genes (Basel). 2016 May 26; 7(6). . View in PubMed
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Prostate. 2016 May; 76(6):597-608. . View in PubMed
Editorial Comment J Urol. 2015 Sep; 194(3):798. . View in PubMed
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy J Natl Cancer Inst. 2015 Jul; 107(7). . View in PubMed
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial Int J Cancer. 2015 Apr 15; 136(8):1856-62. . View in PubMed
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60.. View in PubMed
New prostate cancer drugs: extending and improving life Lancet Oncol. 2014 Sep; 15(10):1052-4. . View in PubMed
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer J Clin Oncol. 2014 Apr 10; 32(11):1136-42. . View in PubMed
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 J Natl Cancer Inst. 2014 Apr; 106(4):dju013. . View in PubMed
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/ß-catenin/CBP pathway Int J Cancer. 2014 Jan 01; 134(1):43-54. . View in PubMed
Circulating tumor cells in prostate cancer Cancers (Basel). 2013 Dec 04; 5(4):1676-90. . View in PubMed
Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol. 2013 Aug; 14(9):893-900. . View in PubMed
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore Ann Oncol. 2013 Jul; 24(7):1717-1720. . View in PubMed
Perillyl alcohol for the treatment of temozolomide-resistant gliomas Mol Cancer Ther. 2012 Nov; 11(11):2462-72. . View in PubMed
Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference Prostate. 2011 Sep 15; 71(13):1390-400. . View in PubMed
Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype Mol Cancer Ther. 2011 Jun; 10(6):938-48. . View in PubMed
Telomerase targeted therapy in cancer and cancer stem cells Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. . View in PubMed
A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter Cancer Res. 2010 Aug 15; 70(16):6420-6. . View in PubMed
Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo Mol Cancer Ther. 2010 Feb; 9(2):438-49. . View in PubMed
Targeted therapy in renal cancer Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. . View in PubMed
Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells Cancer Res. 2006 Jun 01; 66(11):5763-71. . View in PubMed
Cortical variability and asymmetry in normal aging and Alzheimer's disease Cereb Cortex. 1998 Sep; 8(6):492-509. . View in PubMed
Sulcal variability in the Alzheimer's brain: correlations with cognition Neurology. 1998 Jan; 50(1):145-51. . View in PubMed
Dr. Goldkorn is a board-certified medical oncologist and physician-scientist who is clinically subspecialized in genitourinary (GU) malignancies. Dr. Goldkorn’s laboratory is focused on developing the therapeutic and biomarker potential of liquid biopsies, cancer plasticity, and telomerase. His team leads liquid biopsy studies in phase III multi-center GU cancer trials sponsored by the NCI-SWOG cooperative group, where Dr. Goldkorn chairs translational medicine for prostate cancer. Dr. Goldkorn founded and directs a Liquid Biopsy Core at USC Norris, which offers state-of-the-art instrumentation and develops novel workflows for multiparametric analysis of liquid biopsies. In the area of cancer plasticity, Dr. Goldkorn’s group discovered that cancer cells can cyclically lose and regain cancer stem-like properties, and their current work is focused on elucidating epigenetic, epitranscriptomic, and metabolomic mechanisms that mediate this plasticity. Collectively, these research efforts are aimed at surmounting cancer heterogeneity and providing powerful new tools for precision cancer care.
